I think you should not get carried away too much with this year's bonanza earnings. It is unlikely to be repeated in the near future. COVID alone will have gifted ACL about $150m in profits this year, but that will not repeat. I can see PCR testing dropping to 20 000 per day or even less from here. ACL may then be earning about $50m NPAT. That would make the shares reasonable value at the moment, but not a screaming buy.
Personnally I'm holding out for the H1FY22 dividend. Will decide what to do after that.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.77 |
Change
0.005(0.18%) |
Mkt cap ! $544.0M | |||
| Open | High | Low | Value | Volume |
| $2.76 | $2.77 | $2.74 | $94.75K | 34.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 633 | $2.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.77 | 4189 | 15 |
View Market Depth
| Last trade - 11.12am 14/07/2025 (20 minute delay) ? |
| ACL (ASX) Chart |